# PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

> **NCT03365791** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 76 (actual)

## Conditions studied

- Small Cell Lung Cancer
- Gastric Adenocarcinoma
- Esophageal Adenocarcinoma
- Castration Resistant Prostate Adenocarcinoma
- Soft Tissue Sarcoma
- Ovarian Adenocarcinoma
- Advanced Well-differentiated Neuroendocrine Tumors
- Diffuse Large B Cell Lymphoma

## Interventions

- **BIOLOGICAL:** PDR001
- **BIOLOGICAL:** LAG525

## Key facts

- **NCT ID:** NCT03365791
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-24
- **Primary completion:** 2019-02-21
- **Final completion:** 2020-09-17
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2022-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03365791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03365791, "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03365791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*